Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.1
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 25260751
Charlaftis N, et al. (2014) The MEKK1 PHD ubiquitinates TAB1 to activate MAPKs in response to cytokines. EMBO J 33, 2581-96 25260751
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T203-p - ERK1 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
AG490 TGF-beta inhibit treatment-induced increase
NSC697923 TGF-beta inhibit treatment-induced increase
TAK1_inhibitor TGF-beta inhibit treatment-induced increase
EGF increase
NSC697923 EGF inhibit treatment-induced increase
TAK1_inhibitor EGF inhibit treatment-induced increase
AG490 EGF inhibit treatment-induced increase
EGF, TGF-beta MEKK1 (mouse) decrease WT inhibits, mPHD less inhibition

Y205-p - ERK1 (mouse)
Modsite: HtGFLtEyVAtRWyR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
AG490 TGF-beta inhibit treatment-induced increase
NSC697923 TGF-beta inhibit treatment-induced increase
TAK1_inhibitor TGF-beta inhibit treatment-induced increase
EGF increase
NSC697923 EGF inhibit treatment-induced increase
TAK1_inhibitor EGF inhibit treatment-induced increase
AG490 EGF inhibit treatment-induced increase
EGF, TGF-beta MEKK1 (mouse) decrease WT inhibits, mPHD less inhibition

T183-p - ERK2 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
AG490 TGF-beta inhibit treatment-induced increase
NSC697923 TGF-beta inhibit treatment-induced increase
TAK1_inhibitor TGF-beta inhibit treatment-induced increase
EGF increase
NSC697923 EGF inhibit treatment-induced increase
TAK1_inhibitor EGF inhibit treatment-induced increase
AG490 EGF inhibit treatment-induced increase
EGF, TGF-beta MEKK1 (mouse) decrease WT inhibits, mPHD less inhibition

Y185-p - ERK2 (mouse)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
AG490 TGF-beta inhibit treatment-induced increase
NSC697923 TGF-beta inhibit treatment-induced increase
TAK1_inhibitor TGF-beta inhibit treatment-induced increase
EGF increase
NSC697923 EGF inhibit treatment-induced increase
TAK1_inhibitor EGF inhibit treatment-induced increase
AG490 EGF inhibit treatment-induced increase
EGF, TGF-beta MEKK1 (mouse) decrease WT inhibits, mPHD less inhibition

T183-p - JNK1 (mouse)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
AG490 TGF-beta inhibit treatment-induced increase
NSC697923 TGF-beta inhibit treatment-induced increase
TAK1_inhibitor TGF-beta inhibit treatment-induced increase
EGF increase
NSC697923 EGF inhibit treatment-induced increase
TAK1_inhibitor EGF inhibit treatment-induced increase
AG490 EGF inhibit treatment-induced increase
EGF, TGF-beta MEKK1 (mouse) decrease WT inhibits, mPHD less inhibition

Y185-p - JNK1 (mouse)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
AG490 TGF-beta inhibit treatment-induced increase
NSC697923 TGF-beta inhibit treatment-induced increase
TAK1_inhibitor TGF-beta inhibit treatment-induced increase
EGF increase
NSC697923 EGF inhibit treatment-induced increase
TAK1_inhibitor EGF inhibit treatment-induced increase
AG490 EGF inhibit treatment-induced increase
EGF, TGF-beta MEKK1 (mouse) decrease WT inhibits, mPHD less inhibition

S71-p - MEKK1 (mouse)
Modsite: RQLRKVRsVELDQLP SwissProt Entrez-Gene
Orthologous residues
MEKK1 (human): S67‑p, MEKK1 (mouse): S71‑p, MEKK1 (rat): S67‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

T1381-p - MEKK1 (mouse)
Modsite: ARLASKGtGAGEFQG SwissProt Entrez-Gene
Orthologous residues
MEKK1 (human): T1400‑p, MEKK1 (mouse): T1381‑p, MEKK1 (rat): T1381‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

Y182-p - P38A (mouse)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
AG490 TGF-beta inhibit treatment-induced increase
NSC697923 TGF-beta inhibit treatment-induced increase
TAK1_inhibitor TGF-beta inhibit treatment-induced increase
EGF increase
NSC697923 EGF inhibit treatment-induced increase
TAK1_inhibitor EGF inhibit treatment-induced increase
AG490 EGF inhibit treatment-induced increase
EGF, TGF-beta MEKK1 (mouse) decrease WT inhibits, mPHD less inhibition

T185-p - P38A (mouse)
Modsite: EMtGyVAtRWYRAPE SwissProt Entrez-Gene
Orthologous residues
P38A (human): T185‑p, P38A iso2 (human): T185‑p, P38A (mouse): T185‑p, P38A iso3 (mouse): T185‑p, P38A (rat): T185‑p, P38A (salmonid): T186‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
AG490 TGF-beta inhibit treatment-induced increase
NSC697923 TGF-beta inhibit treatment-induced increase
TAK1_inhibitor TGF-beta inhibit treatment-induced increase
EGF increase
NSC697923 EGF inhibit treatment-induced increase
TAK1_inhibitor EGF inhibit treatment-induced increase
AG490 EGF inhibit treatment-induced increase
EGF, TGF-beta MEKK1 (mouse) decrease WT inhibits, mPHD less inhibition

T184-p - TAK1 (mouse)
Modsite: GTACDIQtHMtNNKG SwissProt Entrez-Gene
Orthologous residues
TAK1 (human): T184‑p, TAK1 (mouse): T184‑p, TAK1 iso3 (mouse): T184‑p, TAK1 (rat): T184‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
SB431542 TGF-beta inhibit treatment-induced increase
NSC697923 TGF-beta inhibit treatment-induced increase

T187-p - TAK1 (mouse)
Modsite: CDIQtHMtNNKGsAA SwissProt Entrez-Gene
Orthologous residues
TAK1 (human): T187‑p, TAK1 (mouse): T187‑p, TAK1 iso3 (mouse): T187‑p, TAK1 (rat): T187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
SB431542 TGF-beta inhibit treatment-induced increase
NSC697923 TGF-beta inhibit treatment-induced increase